CTRI/2023/05/052622
Not Yet Recruiting
N/A
Phase I Clinical trial study to explore the feasibility and evaluate the clinical outcomes and safety of keratoplasty using bioengineered decellularized cross-linked human corneal graft in comparison to fresh human corneas: A novel therapeutic approach to combat corneal blindness in India.
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- All India Institute of Medical Sciences
- Status
- Not Yet Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Age aged 18 years of age or above
- •2\.Unilateral/ bilateral infectious keratitis or corneal opacity, satisfying the following criteria:
- •\[The patients undergoing emergency partial\-thickness keratoplasty for corneal infections (severe corneal ulcers or melts, with depth \<80% of corneal thickness and size \< 7mm) or corneal opacities (with depth of opacities upto 400 µm)]
- •3\. Willing to participate and follow\-up for at least 6 months
- •4\.Patient who able to give consent for the intervention. In cases where the patient is not able to give consent, then Legal Acceptable Representative (LAR) will do the same on behalf of patients.
Exclusion Criteria
- •b) Exclusion Criteria:
- •1\.Those with corneal thickness \<450 µm
- •2\.Those with limbus\-to\-limbus extent of corneal infection.
- •3\.Patients with untreated concurrent ocular conditions, such as adnexal problems, infections, retinal pathology and glaucoma
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
Phase 1
A first-in-human clinical study to assess feasibility, safety and antitumor activity of genetically modified T-cells in multiple myelomaEUCTR2019-001264-30-ESniversitätsklinikum Würzburg38
Active, Not Recruiting
Phase 1
A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells in multiple myelomaMultiple myeloma (MM)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2019-001264-30-ITniversitätsklinikum Würzburg38
Suspended
Phase 1/2
A first-in-human clinical study to assess feasibility, safety and antitumor activity of genetically modified T-cells in multiple myeloma2024-512643-23-00Universitaetsklinikum Wuerzburg AöR33
Recruiting
Phase 1
Clinical trial of vagus nerve stimulation therapy in patients with acute ST-elevation myocardial infarctioacute ST-elevation myocardial infarctionacute myocardial infarctionD000072657JPRN-jRCT2052230039oguchi Teruo20
Active, Not Recruiting
N/A
Clinical trial to determine the feasibility and safety of MSV cryopreserved in the treatment of gonartrosisEUCTR2012-004441-32-ESFundación Teknon